Biogen Inc. (BIIB)
NASDAQ: BIIB · Real-Time Price · USD
177.11
-2.79 (-1.55%)
At close: Apr 9, 2026, 4:00 PM EDT
176.80
-0.31 (-0.18%)
After-hours: Apr 9, 2026, 5:29 PM EDT
Biogen Market Cap
Biogen has a market cap or net worth of $25.99 billion as of April 9, 2026. Its market cap has increased by 26.03% in one year.
Market Cap
25.99B
Enterprise Value
28.24B
1-Year Change
26.03%
Ranking
Category
Stock Price
$177.11
Market Cap Chart
Since December 1, 1998, Biogen's market cap has increased from $617.50M to $25.99B, an increase of 4,109.30%. That is a compound annual growth rate of 14.64%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 7, 2026 | 25.77B | -0.18% |
| Dec 31, 2025 | 25.82B | 15.86% |
| Dec 31, 2024 | 22.28B | -40.57% |
| Dec 29, 2023 | 37.50B | -5.97% |
| Dec 30, 2022 | 39.88B | 13.15% |
| Dec 31, 2021 | 35.24B | -6.47% |
| Dec 31, 2020 | 37.68B | -29.63% |
| Dec 31, 2019 | 53.54B | -11.69% |
| Dec 31, 2018 | 60.63B | -10.00% |
| Dec 29, 2017 | 67.37B | 9.19% |
| Dec 30, 2016 | 61.70B | -9.65% |
| Dec 31, 2015 | 68.29B | -14.82% |
| Dec 31, 2014 | 80.16B | 21.39% |
| Dec 31, 2013 | 66.04B | 90.69% |
| Dec 31, 2012 | 34.63B | 29.54% |
| Dec 30, 2011 | 26.73B | 67.31% |
| Dec 31, 2010 | 15.98B | 3.27% |
| Dec 31, 2009 | 15.47B | 11.34% |
| Dec 31, 2008 | 13.90B | -16.78% |
| Dec 31, 2007 | 16.70B | 0.70% |
| Dec 29, 2006 | 16.58B | 7.90% |
| Dec 30, 2005 | 15.37B | -30.83% |
| Dec 31, 2004 | 22.22B | 288.89% |
| Dec 31, 2003 | 5.71B | 12.55% |
| Dec 31, 2002 | 5.08B | -51.71% |
View and export this data all the way back to 1998. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| AstraZeneca | 317.11B |
| Merck & Co. | 304.55B |
| Novartis AG | 292.80B |
| Amgen | 188.79B |
| Gilead Sciences | 175.68B |
| Novo Nordisk | 166.69B |
| Pfizer | 156.26B |
| Bristol-Myers Squibb Company | 120.87B |